In a recent issue of Breast Cancer Research, Guo and colleagues provided mechanistic evidence supporting the role for microRNA (miR)-510 as a novel oncomir playing a pivotal role in human breast cancer via regulation of expression of peroxiredoxin 1 [1] . Their study follows the original observation of elevated miR-510 expression in human breast tumor samples described by Findlay and colleagues in 2008 [2] .
To acquire a deeper insight into the potential role of miR-510 in human breast cancer, we carried out an in silico analysis of the miR-510 abundance in clinical breast cancer samples using three independent publically available datasets (described in Additional file 1). Conspicuously, we have found that expression of miR-510 was virtually nonexistent in clinical sample sets (Dataset 1 [3] and Dataset 2 [4] ). Only seven out of 473 clinical breast cancer specimens altogether demonstrated the miR-510 miRNA-Seq reads ( Figure 1A ,B, left), all of which could be attributed to a very low spectrum of the whole expression range of all miRNAs expressed in the respective datasets ( Figure 1A ,B, right). Analysis of the same kind carried out in 11 normal tissue samples (included in Dataset 2 [4] ) revealed one sample expressing a low level of the miR-510 gene ( Figure 1C ). Similarly, one out of six breast cancer cell lines (included in Dataset 2) showed detectable expression of miR-510 ( Figure 1D) .
Analysis of an independent dataset (Dataset 3 [5] ) showed expression of miR-510 in a substantial number of cases studied. One should, however, consider that, similar to the previously mentioned miRNA-Seq experiments, the expression of miR-510 in Dataset 3 could be attributed to the very low spectrum of the expression range (Figure 2A) , and consider that microarray results are by their nature characterized by a very modest signalto-noise separation, resulting in a low estimation confidence for the low readouts. Nevertheless, we did attempt to assess whether stratification of Dataset 3 by the median expression signal of miR-510 would correlate with the disease-free survival time ( Figure 2B) . Results of the analysis revealed that, although the higher strata of miR-510 expression showed a tendency to correlate with slightly worse disease-free survival times ( Figure 2B ), the correlation did not reach statistical significance (P = 1.88 × 10
−1
). Considering our observations and acknowledging the high clarity of mechanistic observations by Guo and colleagues [1] , we assume that miR-510 ought to be further evaluated in human cancer types other than breast cancer, especially those in which peroxiredoxin 1 seems to play a role. 
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